Pentavalent Vaccine and its Effect on Healthcare
The World Health Organization (WHO) considers infant vaccination the most influential health intervention for promoting a healthy society. Infant vaccination programs have been merged into public health service networks from their starting point in Iran. With 98% of infants vaccinated, it has brought great success in eradicating, removing and controlling preventable diseases.
The Pentavalent vaccine is used to prevent hepatitis B, Diphtheria, anthrax, Tetanus and Haemophilus influenzae type b (Hib) flu and is injected in three different time intervals (2, 4 and 6 months). This vaccine is used broadly in more than 100 countries for preventing Diphtheria, Tetanus, and Pertussis (DPT), Hepatitis B and Hib in recent years. Some of the Pentavalent vaccine advantages include reducing the number of injections and syringes used, less pain and restlessness in infants, decreasing the complications of injection, ease of planning, increasing cost effectiveness and increasing the immunization coverage.
Due to importance of vaccines for society healthcare, SOBHAN Recombinant Protein Co have established in 2014 to produce High-Tech vaccines. Over the last decade, SOBHAN has been grown to an investor company dedicated to technology transferring, manufacturing and marketing in the field of vaccine and biopharmaceuticals so that it is one of the top knowledge-based companies in Iran. Capable of technology development and transfer, SOBHAN manages cooperation projects between university and industry, more over supporting the state-of-the-art technologies and providing economical consultancy and market analysis.
The company vision is developing and delivering breakthrough medicines and increasing accessibility and affordability of existing medicines to patients. Pursuing the vision, their unique platform for manufacturing biopharmaceutical products is being built adhering to FDA and EMA regulations.
SOBHAN is equipped to develop and manufacture biological products through genetic engineering, bacterial and yeast fermentation, purification and fill & finish technology. The quality management team works diligently to meet and surpass international regulations & GMP requirements, and their diverse capabilities allow them to offer clients non-stop service to their needs, While devoting themselves to manufacturing biopharmaceutical products.
Advanced Vaccines
SOBHAN has begun producing vaccines, including Hepatitis, Meningitis, Pentavalent and Influenza vaccines, based on international standards and with a vision to local and international markets. The complete procedure from production until packaging is designed and operated with the collaboration of pioneering Europeans in this field and under the supervision of leading international technology owners.
Pentavalent Vaccine
Pentavalent combines five different vaccines in a single vial to protect against five diseases: diphtheria-pertussis-tetanus (DTP), hepatitis B (HepB) and Haemophilus influenzae type B (Hib).
Offering HepB and Hib vaccines as part of a five-in-one conjugate Pentavalent vaccine doesn’t just improve coverage, it also means that just three shots are needed instead of the usual nine to provide the same cover from separate vaccines (three each for DTP, HepB and Hib vaccines).
Other advantages include:
- Widespread protection is achieved quickly and safely;
- Shipping costs are lower;
- With fewer syringes to dispose of, environmental impact is reduced;
- Fewer injections mean less distress for children and parents
Components are described below.
– Diphtheria toxoid: a sub-unit antibacterial vaccine, made from the modified toxin (poison) produced by the bacteria Corynebacterium diphtheriae. The vaccine protects against diphtheria.
– Pertussis vaccine: an inactivated antibacterial vaccine, which contains killed whole bacterial cells. It protects against pertussis.
– Tetanus toxoid (TT): a sub-unit antibacterial vaccine made from the modified toxin produced by Clostridium tetani.
– Haemophilus influenzae type b (Hib): a conjugate antibacterial vaccine, which protects against pneumonia and meningitis caused by Haemophilus influenzae type b.
These bacteria are the most common cause of bacterial meningitis in children under five years of age in countries where Hib vaccine is not routinely given to all infants. Meningitis refers to severe infection of the membranes surrounding the brain and spinal cord, which can rapidly lead to high fever, paralysis and death. Haemophilus influenzae type b bacteria are also the second most common cause of bacterial pneumonia in children. Pneumonia is a severe infection of the lungs, which causes the air sacs to fill with fluid and pus; this makes breathing painful and difficult, and reduces the oxygen entering into body.
SOBHAN has prepared all components and the formulation technology has been taken from an Indian company as a tech transfer project, under supervision of a European company.
Meningitis Vaccine
Meningitis is an acute inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges. The inflammation may be caused by infection with viruses, bacteria, or other microorganisms, and less commonly by certain drugs. Meningococcal vaccines protect against most types of meningococcal disease, although they do not prevent all cases. Two kinds of vaccines have been developed to protect against Neisseria meningitides: meningococcal polysaccharide vaccine, and meningococcal conjugate vaccine. Meningococcal vaccines exist against groups A, B, C, W135 and Y. In countries where the vaccine for meningococcal group C was introduced, cases by this pathogen have decreased substantially. A quadrivalent vaccine now exists, which combines all four vaccines.
In SOBHAN, Meningitis quadrivalent (ACWY) is in the final steps of pilot production, while a unique production site with first class facilities, QA and QC systems is under construction adhering to FDA and EMA regulations.
Technology transfer
SOBHAN has used its expertise to transfer the complete production technology of the Hepatitis vaccine to a local company. Moreover, with recent agreements made with Russian companies, this technology is on its way to Russia. SOBHAN is now ready to transfer the production technology of recombinant vaccines to any local and international companies with required certificates.
Research and Development
SOBHAN is collaborating with domestic and international universities and research institutes, using the excellent expertise of its team in the following fields: Microbiology, Genetics, Protein Engineering, fermentation and formulation. SOBHAN employs professional researchers and possesses advanced equipment which have obtained great achievements in production promotion and process engineering.
Pardis Technology Park (PTP)
Technology facilitators play an important role in a knowledge based economy. Developing new products and services in all stages of TRL (Technology Readiness Level) depends on scientific and technological infrastructures.
Technology parks are very important in the road map to successfully implementing science and technology for society benefits . Pardis Tech Park, under the supervision of vice-presidency of science and technology of Iran, gathers and supports high-tech and knowledge based company in Iran. The park have supported more than 250 companies and also support for marketing and sale. For instance, the Techmart network provide a platform between supplier and provider in one side and request for technological solution in another side and make a bridge between supply and demand.
The D8 Technology Exchange Network secretariat, in Pardis Technology Park, are welcomed cooperation and collaboration to increase synergy and extend innovation and technology solution for solving problems among D8 countries.
SOBHAN Co also enjoys the facilities of attending in Pardis Tech Park as the best R&D center and Technology Park and technology paradise in the MENA.
For more information about Pardis Technology Park and SOBHAN Co please see references website.
